Pazopanib for the treatment of renal cell carcinoma

被引：16
|
作者：
Welsh, Sarah J. [1 ]
Fife, Kate [1 ]
机构：
[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 0QQ, England
来源：
FUTURE ONCOLOGY | 2015年 / 11卷 / 08期
关键词：
antiangiogenic; kidney; pazopanib; renal cancer; treatment; tyrosine kinase inhibitor; DOUBLE-BLIND; PHASE-III; TARGETED THERAPIES; SUNITINIB; SAFETY; EFFICACY; TRIAL;
D O I：
10.2217/fon.14.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence and mortality from renal cell cancer (RCC) is increasing. RCC tumors are particularly vascular in nature as a result of disruption of the VHL gene and/or its upstream pathway leading to upregulation of the hypoxia-inducible factor transcription factor. The hypoxia-inducible factor pathway drives angiogenesis by upregulating VEGF and bFGF, amongst other proangiogenic downstream target genes. Therapies which target angiogenesis have been successful in treating metastatic RCC (mRCC) and the receptor tyrosine kinase inhibitor, pazopanib, is licensed for first line treatment of mRCC. This review details the past, current and future roles of pazopanib in the treatment of mRCC.
引用
收藏
页码：1169 / 1179
页数：11
相关论文
共 50 条
  • [41] Recurrent Pneumothorax As A Complication Of Treatment With Pazopanib: First Case Report In Metastatic Renal Cell Carcinoma
    Towns, C. R.
    Brockway, B. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [42] Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma
    Bonate, Peter L.
    Suttle, A. Benjamin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 231 - 240
  • [43] Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in Greece
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Bournakis, E.
    Boutis, A.
    Koutsoukos, K.
    Syrios, J.
    Tzovaras, A.
    Chatzikou, M.
    Michailidi, C.
    Maniadakis, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma
    Ebinc, Senar
    Kalkan, Ziya
    Oruc, Zeynep
    Urakci, Zuhat
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (04): : 226 - 234
  • [45] Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
    Sternberg, Cora N.
    Donskov, Frede
    Haas, Naomi B.
    Doehn, Christian
    Russo, Paul
    Elmeliegy, Mohamed
    Baneyx, Guillaume
    Banerjee, Hiya
    Aimone, Paola
    Motzer, Robert J.
    CLINICAL CANCER RESEARCH, 2018, 24 (13) : 3005 - 3013
  • [46] Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma
    Penttila, Patrick
    Rautiola, Juhana
    Poussa, Tuija
    Peltola, Katriina
    Bono, Petri
    CLINICAL GENITOURINARY CANCER, 2017, 15 (03) : 384 - 390
  • [47] Renal cell carcinoma with a more favorable basis with pazopanib keitsprofil?
    不详
    UROLOGE, 2011, 50 (01): : 140 - 140
  • [48] Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma
    Bukowski, Ronald M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (05) : 635 - 645
  • [49] THE EFFECTS OF PAZOPANIB VERSUS SUNITINIB ON RENAL OUTCOME IN METASTATIC RENAL CELL CARCINOMA
    Lee, Eun Jeong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 561 - 561
  • [50] Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
    Pick, Amy M.
    Cochrane, Zara Risoldi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2013, 2 (02) : 117 - 118
12345